ADA took place in Orlando, FL., June 21–24, 2024. 

The American Society of Clinical Oncology (ASCO), took place in Chicago, May 31st - June 4th, 2024. We were present at our partner Personalis' booth #30149. If you missed us, contact us to learn more about how our proprietary, non-invasive 5hmC epigenomic platform...

We will be at Digestive Disease Week, Washington, DC, May 18th to 21st, 2024. Don't miss our presentation, titled: “Detection of High-Risk Pancreatic Cysts using Avantect™ blood-based test.” 

The American Medical Association CPT Editorial Panel Meeting took place in Chicago, May 9th to 11th, 2024.

At the American Association for Cancer Research meeting, April 2024 – we presented a poster titled “Plasma cell-free DNA hydroxymethylation profiling reveals anti-PD1 treatment response and resistance biology in non-small cell lung cancer.” 

We attended TRI-CON 2024. If you missed us, contact us to learn about Virtuoso, our epigenomic platform that provides an unprecedented level of clarity to inform cancer diagnosis and treatment. Or, get more information on our presentation! Epigenomic Tools for Early...

European Neuroendocrine Tumor Society, March 2024 – Oral presentation entitled “ 5-Hydroxymethylcytosine profiling of plasma-derived circulating free DNA in patients with pancreatic neuroendocrine tumors treated with [177Lu]Lu-DOTA-TATE.” 

Circulating Nucleic Acids in Plasma Symposium, March 2024 – Oral presentation entitled “Plasma cell-free DNA hydroxymethylation profiling reveals anti-PD1 treatment response and resistance biology in non-small cell lung cancer.” 

PRECEDE – The Pancreatic Cancer Early Detection Consortium, December 6th, and 7th , 2023 

American Pancreatic Association, December 2023 – Poster presentation “SAFE-D Trial design: Targeted pancreatic cancer screening to evaluate stage and resectability rate shift in patients with new-onset diabetes.”